Brought to you by

Valeant gets $3.2bn through sale of debt
28 Jun 2013
Executive Summary
Valeant Pharmaceuticals International Inc. has sold $3.2bn in notes to VPII Escrow Corp. The company issued $1.6bn of its 6.75% senior unsecured notes due 2018 and $1.625bn of its 7.5% senior unsecured notes due 2021. Valeant will use the proceeds, along with the $2bn it netted via a concurrent FOPO, to help finance its $8.7bn acquisition of Bausch & Lomb Inc.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Financing
- Nonconvertible Debt
- Private Placement
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com